By :- Subhi Sharma
Around 7.5 million people have died in the year 2007….and people suffering has already crossed the stats…of I suppose 10 million…cancer is a breath taking disease which has.spread like a web all around the world.
Many population groups across the United States and around the world suffer disproportionately from cancer and its after-effects. Overcoming cancer health disparities is one of the best opportunities we have for lessening the burden of cancer. NCI supports research to identify and understand the factors that contribute to disparities. NCI also funds studies to develop and disseminate culturally appropriate interventions.
“Health disparities occur when one group of people has a higher incidence or mortality rate than another, or when survival rates are less for one group than another.”
Here is new growth in the research of cancer which may be able to release pain of……..some suffrers………..who are yet fighting back for their healthy and peaceful life
Archimedes Pharma Ltd., and its subsidiary, Archimedes Pharma U.S. Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Lazanda® (fentanyl) nasal spray . It will be used for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Lazanda tags the first FDA product approval for Archimedes Pharma.
Lazanda is marketed as PecFent® (fentanyl pectin nasal spray) in Europe, where it is presently available in five countries.
Breakthrough pain in cancer (BTPc) is an intense, sudden pain that is often unpredictable and debilitating and occurs despite otherwise appropriate opioid therapy for background pain. BTPc often has high intensity, a rapid onset, usually reaching maximum intensity within five minutes, and a short duration, lasting between 30 and 60 minutes per episode. On average, BTPc affects more than half of patients with cancer and often interferes with patients’ health and ability to engage in daily living activities.
“As the first fentanyl nasal spray in the U.S., Lazanda provides a new approach to managing the often debilitating and inadequately-treated episodes of breakthrough pain that many patients with cancer experience Lazanda will be available in the second half of this year through a Risk Evaluation and Mitigation Strategy (REMS) program, which is intended to minimize the risk of misuse, abuse, addiction, overdose, and serious complications due to medication errors. Under the Lazanda® REMS program, pharmacies, distributors, and health care professionals who prescribe to outpatients are required to enroll in the program to dispense, distribute, and prescribe Lazanda.
The Center to Reduce Cancer Health Disparities is the cornerstone of the [NATIONAL CANCER INSTITUTE ] NCI’s efforts to reduce the unequal burden of cancer in our society. The Center is committed to improving our understanding of the causes of disparities and reducing and eliminating them.
For more research studies & cancer related Queries visit :- http://crchd.cancer.gov/